Organogenesis (NASDAQ:ORGO) Issues Quarterly Earnings Results

Organogenesis (NASDAQ:ORGO) announced its earnings results on Thursday. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11, Zacks reports. The firm had revenue of $150.86 million for the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a positive return on equity of 4.05% and a negative net margin of 1.30%. Organogenesis updated its FY 2025 guidance to EPS.

Organogenesis Trading Up 44.7%

Shares of ORGO stock traded up $1.74 during trading on Friday, reaching $5.63. 32,983,255 shares of the company’s stock traded hands, compared to its average volume of 722,316. The firm’s 50-day moving average is $4.43 and its 200 day moving average is $4.19. The company has a market capitalization of $714.22 million, a P/E ratio of -46.92 and a beta of 1.68. Organogenesis has a 1 year low of $2.61 and a 1 year high of $6.71.

Analysts Set New Price Targets

Several research firms have weighed in on ORGO. Cantor Fitzgerald boosted their price objective on Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Organogenesis in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday. Finally, BTIG Research reiterated a “buy” rating and issued a $7.00 target price on shares of Organogenesis in a research note on Friday, September 26th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.33.

Hedge Funds Weigh In On Organogenesis

Large investors have recently made changes to their positions in the stock. Walleye Capital LLC purchased a new position in shares of Organogenesis in the second quarter valued at $45,000. Tower Research Capital LLC TRC lifted its holdings in Organogenesis by 590.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 23,655 shares of the company’s stock worth $87,000 after purchasing an additional 20,228 shares in the last quarter. Strs Ohio bought a new position in Organogenesis in the 1st quarter worth about $105,000. Creative Planning grew its holdings in Organogenesis by 84.5% during the 2nd quarter. Creative Planning now owns 35,392 shares of the company’s stock valued at $130,000 after buying an additional 16,205 shares in the last quarter. Finally, Cetera Investment Advisers bought a new stake in shares of Organogenesis during the second quarter valued at about $222,000. 49.57% of the stock is owned by institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.